Urine Calcium and Bone Mineral Density in Calcium Stone-Forming Patients Treated with Alendronate and Hydrochlorothiazide

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Urologia internationalis

• Publication date

  2016-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000443484PMID 26800461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous and long‐term treatment is more important than dosage for the protective effect of thiazide use on bone metabolism and fracture risk

  2016cited by this paper
• Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options

  2015cited by this paper
• Treatment of osteoporosis in older adults.

  2014cited by this paper
• Incidence of Osteoporosis in Patients with Urolithiasis

  2014cited by this paper
• Pharmacologic treatment of kidney stone disease.

  2013cited by this paper
• Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones

  2013cited by this paper
• Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.

  2013cited by this paper
• Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.

  2012cited by this paper
• Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

  2011cited by this paper
• Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion?

  2011cited by this paper
• Mineral density and bone remodelling markers in patients with calcium lithiasis

  2011cited by this paper
• [New therapy using bisphosphonate for urolithiasis].

  2011cited by this paper
• Alendronate Reduces the Excretion of Risk Factors for Calcium Phosphate Stone Formation in Postmenopausal Women with Osteoporosis

  2009cited by this paper
• Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.

  2009cited by this paper
• Economics of stone management.

  2007cited by this paper
• Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis.

  2007cited by this paper
• Renal lithiasis and nutrition

  2006cited by this paper
• Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides.

  2006cited by this paper
• Effect of Indapamide on Urinary Calcium Excretion in Patients with and without Urinary Stone Disease

  2005cited by this paper
• Intravenous Pamidronate Prevents Femoral Bone Loss and Renal Stone Formation During 90‐Day Bed Rest

  2004cited by this paper
• Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model

  2004cited by this paper
• Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics.

  2004cited by this paper
• Osteoporosis and Urolithiasis

  2004cited by this paper
• Increased bone mineral density in a population‐based group of 70‐year‐old women on thiazide diuretics, independent of parathyroid hormone levels

  2001cited by this paper
• Low-Dose Hydrochlorothiazide and Preservation of Bone Mineral Density in Older Adults

  2000cited by this paper
• Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.

  2000cited by this paper
• Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.

  1999cited by this paper
• Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria.

  1998cited by this paper
• [Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis].

  1996cited by this paper
• Prevention of hypercalciuria and stone‐forming propensity during prolonged bedrest by alendronate

  1995cited by this paper

• Spectroscopic methods for the simultaneous determination of amlodipine besylate and Hydrochlorothiazide in their binary mixture and pharmaceutical dosage form

  2026cites this paper
• Update - 2022 Canadian Urological Association guideline: Evaluation and medical management of the kidney stone patient.

  2022cites this paper
• CUAJ – CUA Guideline Bhojani et al CUA guideline: Kidney stones

  2022cites this paper
• CUA GUIDELINE UPDATE – Canadian Urological Association guideline: Evaluation and medical management of kidney stones

  2022cites this paper
• Diagnostic et stratégie thérapeutique de la lithiase urinaire

  2022cites this paper
• The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

  2021cites this paper
• The impact of thiazide diuretics on bone mineral density and the trabecular bone score: The Rotterdam study.

  2020cites this paper
• The Impact of Thiazides and Potassium Citrate on Bone Mineral Density Evaluated by CT Scan in Stone Formers

  2018cites this paper
• [Metabolic study. How to make it accessible, useful and generalized.]

  2017cites this paper
• Predictive Variables of Success in Extracorporeal Shock Wave Lithotripsy

  2017cites this paper